Friday 6 November 2026 Export NXTS’s income statement to Excel — free account

Nexentis Technologies Inc.

NXTS Basic Materials Agricultural Inputs

Nexentis Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $210,000.00, down 20.2% from fiscal 2023.

Revenue: −100.0%
EPS: +69.0%
Free cash flow: −2.86%
Total debt: −39.6%

Quarter to June 2026, against a year earlier

0.49 0.07 −12.50%

Follow NXTS

Alert me

Market cap: $1.4M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: −9.26
Beneish M: −1.38
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 0.00

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 1.42

Revenue ttm 0.21

Net income ttm (16.14)

Free cash flow ttm (4.51)

Net debt Q (8.50)

Valuation

P/E 0.00

Forward P/E 0.00

Price / sales 1.92

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.22

Financial health

Current ratio Q 3.72

Debt / equity Q 0.24

Interest coverage Q (0.21)

Growth

Revenue growth Q −100.00%

Operating income growth Q +28.63%

EPS, this year —

EPS, next year A —

Revenue, next year A +3,066.29%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.07%

10-year low 10-year high

P/B against its own 10 years 9.52%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	2	4	9
Receivables	0	0	0	—
Inventory	0	0	—	—
Other	0	0	0	0
	5	3	6	10

	2023	2024	2025	Q'26
Payables	0	0	0	0
ST’ Debt	—	—	1	0
Other	1	1	0	3
	1	1	1	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.62%	(21.74%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	39.96%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(10.74)	(13.67)	—	—	—
’25	(85.25)	(44.04)	6.79	3.68	(60.25)
’24	(63.62)	(56.28)	(95.43)	(30.05)	(217.77)
’23	(633.54)	(171.23)	(435.53)	(240.72)	(1.33k)
’22	(804.76)	(753.39)	(821.88)	(428.06)	(2.81k)
’21	(530.80)	(1.19k)	(787.64)	(975.99)	(3.53k)
’20	(433.25)	(682.26)	(481.09)	(214.39)	(1.80k)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	0	—	—
’24	0	0	0	0	0
’23	0	0	—	0	0
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	0	—	—	0	0
’19	—	—	—	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	(1)	(1)	(4)
’24	(1)	(1)	(1)	0	(3)
’23	(1)	(1)	(1)	(1)	(3)
’22	(1)	(1)	(2)	(1)	(5)
’21	0	(2)	(1)	(1)	(4)
’20	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	(1)	(2)	(4)
’24	(1)	(1)	(1)	0	(3)
’23	(1)	(1)	(1)	(1)	(3)
’22	(1)	(1)	(2)	(1)	(5)
’21	0	(2)	(1)	(1)	(4)
’20	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	0	0	0	0	0	0	0	—	0		(5.2%)	—	—	—	—
	Gross margin, %	23.60	58.80	67.91	17.80	81.32	68.98	59.82	79.09	21.43	—	(113.94)		(2.2) pt	Powerpack Nexentis Technologies Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	(1)	0	(2)	(2)	(5)	(6)	(7)	(4)	(4)	(17)		+15.9%
	EBT margin, %	(296.83)	(278.48)	(104.31)	(1,132.20)	(691.61)	(1,110.57)	(1,466.95)	(2,760.46)	(2,056.67)	0.00	(8,048.08)		+296.8 pt
	Net income	(1)	0	0	(2)	(2)	(5)	(6)	(7)	(5)	(4)	(16)		+24.0%
Per share, $
Per share, $	Revenue	3.73	1.55	3.14	219.75	258.11	312.93	179.09	53.67	8.80	0.00	0.25		n/m
	Earnings	(6.93)	(3.03)	(2.62)	(2,393.24)	(1,797.87)	(3,527.25)	(2,808.10)	(1,328.62)	(217.77)	(24.77)	(17.58)		+15.2%
	Cash flow	(7.53)	(2.81)	(3.72)	(1,556.00)	(887.44)	(2,938.07)	(2,316.86)	(660.00)	(143.28)	(23.52)	(5.43)		+13.5%
	Capex	0.00	0.00	0.00	(29.12)	1.11	(48.36)	(23.50)	4.69	0.00	(0.07)	(0.11)		n/m
	Free cash flow	(7.53)	(2.81)	(3.72)	(1,585.12)	(886.33)	(2,986.43)	(2,340.36)	(655.31)	(143.28)	(23.59)	(5.53)		+13.5%
	Book value	0.00	(1.98)	1.60	(502.62)	(517.22)	4,580.43	2,607.86	1,317.96	191.64	97.16	2.18		n/m
	Shares, m	0	0	0	0	0	0	0	0	0	0	0		+7.2%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00		0.0
	P/S	0.00	0.00	0.00	0.00	0.00	21.97	7.75	6.92	13.22	—	1.92		5.5
	P/B	0.00	0.00	0.00	0.00	0.00	1.50	0.53	0.52	0.61	—	0.22		0.4
	EV/Sales	0.00	0.00	0.00	0.00	0.00	6.66	(6.57)	(2.12)	8.37	—	(38.93)		0.7
	EV/FCF	0.00	0.00	0.00	0.00	(16.57)	(0.69)	0.50	0.32	(0.51)	—	1.79		(1.9)
Cash, $m
Cash, $m	Operating cash flow	(1)	(1)	(1)	(1)	(1)	(4)	(5)	(3)	(3)	(4)	(4)		+21.7%
	Capex	—	0	0	0	0	0	0	0	—	0	0		(18.1%)
	Free cash flow	(1)	(1)	(1)	(1)	(1)	(4)	(5)	(3)	(3)	(4)	(5)		+21.7%
Balance, $m
Balance, $m	Working capital	(1)	(1)	0	0	0	6	6	5	3	5	8		n/m
	Net debt	0	0	0	0	0	(7)	(6)	(4)	(2)	(3)	(8)		n/m
	Shareholders’ equity	—	0	0	0	0	6	6	6	5	16	2		n/m
Returns, %
Returns, %	ROA	(123.05)	(306.20)	(54.98)	(258.73)	(235.61)	(116.37)	(81.47)	(94.96)	(81.72)	(30.95)	(121.21)		+92.1 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(3,919.45)	(239.20)	(87.57)	(20.98)	0.00		(21.0) pt
	ROE	119.77	134.27	323.72	2,143.99	367.24	(162.12)	(94.48)	(106.96)	(94.15)	(39.44)	(437.12)		(159.2) pt
People
People	Employees	—	—	—	—	6	10	8	3	5	9	—		+8.4%
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.04	0.04	0.05	0.09	0.04	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UAN CVR Partners, LP	$1.2B	10.8×	—	−10.64% (below 0%: shrinking)	n/m	+5.14% (above 0%: growing)	21.70%	(2.49%)	Compare
FMC FMC Corporation	$944.2M	— (loss-making)	— (loss-making)	−80.47% (below 0%: shrinking)	n/m	+90.90% (above 0%: growing)	(379.23%)	(1,050.24%)	Compare
IPI Intrepid Potash, Inc	$422.1M	16.9×	— (loss-making)	−4.11% (below 0%: shrinking)	−54.76% (below 0%: shrinking)	−85.77% (below 0%: shrinking)	19.68%	0.41%	Compare
LVROF Lavoro Limited	$34.8M	— (loss-making)	— (loss-making)	−23.62% (below 0%: shrinking)	n/m	−6.85% (below 0%: shrinking)	15.65%	0.67%	Compare
AVD American Vanguard Corporation	$28.0M	— (loss-making)	11.4×	−9.71% (below 0%: shrinking)	n/m	−33.18% (below 0%: shrinking)	29.73%	(0.26%)	Compare
BIOX Bioceres Crop Solutions Corp.	$13.6M	— (loss-making)	27.0×	−34.73% (below 0%: shrinking)	n/m	+344.29% (above 0%: growing)	32.23%	(10.91%)	Compare
SEED Origin Agritech Limited	$10.0M	— (loss-making)	— (loss-making)	+432.86% (above 0%: growing)	n/m	−107.51% (below 0%: shrinking)	22.38%	0.00%	Compare
BHILQ Benson Hill, Inc.	$1.5M	— (loss-making)	— (loss-making)	+45.32% (above 0%: growing)	n/m	+56.10% (above 0%: growing)	(1.34%)	(57.94%)	Compare
NXTS Nexentis Technologies Inc.	$1.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−2.86% (below 0%: shrinking)	0.00%	0.00%
Median of peers	$31.4M	—	—	−10.18%	—	−0.86%	20.69%	(1.37%)

All 15 Agricultural Inputs stocks →

Pay and ownership Proxy statement filed 12 March 2026

Ownership

Directors and executive officers, together 6.52%

SciSparc Ltd. 9.60%

Dr. Alon Silberman 9.32%

L.I.A. Pure Capital Ltd. 6.19%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Nexentis Technologies Inc. (NXTS) Latest News

29 Oct

Impact 3 · 7:22 AM · GlobeNewswire

Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz

26 Oct

Impact 3 · 8:16 AM · GlobeNewswire

Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

12 Oct

Impact 3 · 8:07 AM · GlobeNewswire

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

7 Oct

Impact 3 · 10:03 AM · InvestorsHub

Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud

Impact 3 · 7:32 AM · GlobeNewswire

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

24 Sep

Impact 3 · 7:50 AM · GlobeNewswire

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

23 Sep

Impact 3 · 7:07 AM · GlobeNewswire

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

7 Jul

Impact 3 · 8:25 AM

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative

29 Jun

Impact 3 · 10:10 AM · InvestorsHub

Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)

Impact 3 · 8:20 AM

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

22 Jun

Impact 4 · 8:22 AM · GlobeNewswire

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

17 Jun

Impact 3 · 7:32 AM

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

18 May

Impact 3 · 9:30 AM · GlobeNewswire

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

13 May

Impact 4 · 7:07 AM · GlobeNewswire

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

5 May

Impact 3 · 7:32 AM · GlobeNewswire

Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™

25 Feb

Impact 4 · 8:30 AM · GlobeNewswire

N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company

12 Feb

Impact 4 · 7:25 AM · GlobeNewswire

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

2 Feb

Impact 4 · 8:05 AM · GlobeNewswire

In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

22 Jan

Impact 4 · 7:32 AM · GlobeNewswire

N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

Impact 3 · 10:30 AM

BC-Most Active Stocks

15 Jan

Impact 4 · 8:32 AM · GlobeNewswire

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

5 Jan

Impact 4 · 9:20 AM

N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake

29 Dec

Impact 4 · 8:22 AM · GlobeNewswire

N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

18 Nov

Impact 4 · 9:12 AM · GlobeNewswire

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

30 Oct

Impact 4 · 9:25 AM · GlobeNewswire

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

23 Oct

Impact 4 · 4:03 PM · GlobeNewswire

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Impact 4 · 8:25 AM · GlobeNewswire

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

8 Oct

Impact 3 · 9:00 AM · GlobeNewswire

N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement

29 Sep

Impact 4 · 4:03 PM · GlobeNewswire

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

25 Sep

Impact 4 · 4:01 PM · GlobeNewswire

N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Nexentis Technologies Inc. vs peers in Agricultural Inputs (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 12 March 2026

Ownership

Nexentis Technologies Inc. (NXTS) Latest News

29 Oct

26 Oct

12 Oct

7 Oct

24 Sep

23 Sep

7 Jul

29 Jun

22 Jun

17 Jun

18 May

13 May

5 May

25 Feb

12 Feb

2 Feb

22 Jan

15 Jan

5 Jan

29 Dec

18 Nov

30 Oct

23 Oct

8 Oct

29 Sep

25 Sep

Stockrow Weekly